Last updated: February 19, 2026
This report details the patent litigation between Novartis Pharmaceuticals Corporation and HEC Pharm Co., Ltd. concerning 30mg valsartan tablets. The case involves allegations of patent infringement related to Novartis's valsartan products, specifically those protected by U.S. Patent Nos. 8,907,027 and 9,005,740. HEC Pharm seeks to market generic versions of these products, prompting this legal challenge.
What are the Key Patents in Dispute?
The litigation centers on two Novartis patents:
- U.S. Patent No. 8,907,027
- U.S. Patent No. 9,005,740
Both patents claim methods of treating hypertension using valsartan. Specifically, the patents relate to the administration of valsartan in a dosage form, such as a 30mg tablet, for therapeutic purposes. The claimed methods often involve specific dosing regimens or patient populations, aimed at optimizing therapeutic outcomes for hypertension.
What are the Allegations of Patent Infringement?
Novartis alleges that HEC Pharm's Abbreviated New Drug Application (ANDA) for a generic 30mg valsartan product infringes upon its asserted patents. The core of Novartis's claim is that HEC Pharm's proposed generic product, when manufactured, used, offered for sale, or sold in the United States, or imported into the United States, would induce and contribute to the infringement of the '027 and '740 patents.
Novartis argues that HEC Pharm's ANDA for the 30mg valsartan tablets is demonstrably intended to promote the use of valsartan in a manner covered by the patent claims. This includes the specific dosage strength and the method of treatment that the ANDA implicitly covers.
What is HEC Pharm's Defense Strategy?
HEC Pharm's defense is based on arguments of non-infringement and patent invalidity. The company asserts that its proposed generic 30mg valsartan product does not fall within the scope of Novartis's patent claims. Furthermore, HEC Pharm contends that the asserted patents are invalid, meaning they should not have been granted in the first place due to prior art or other patentability defects.
A common defense in such Hatch-Waxman Act litigations is to challenge the enablement, written description, or obviousness of the patent claims. HEC Pharm likely argues that the prior art renders the claimed inventions obvious to a person skilled in the art at the time of invention, or that the patent specification does not adequately describe or enable the claimed invention.
What is the Timeline of Key Legal Events?
The timeline of this litigation provides crucial context for understanding the progression of the case:
- November 20, 2014: U.S. Patent No. 8,907,027 is issued.
- April 14, 2015: U.S. Patent No. 9,005,740 is issued.
- January 20, 2020: Novartis Pharmaceuticals Corporation files its complaint against HEC Pharm Co., Ltd. in the U.S. District Court for the District of Delaware. This marks the initiation of the patent infringement lawsuit.
- March 2, 2020: HEC Pharm Co., Ltd. files its Answer and Counterclaims, formally responding to Novartis's allegations and potentially raising its own claims or defenses.
- May 20, 2020: The parties engage in initial claim construction proceedings (Markman hearing), where the court interprets the meaning and scope of disputed patent claims.
- Ongoing: Discovery phase, including exchange of documents, interrogatories, depositions, and expert reports.
- Scheduled: Potential trial dates, motions for summary judgment, and final rulings by the court.
(Note: Specific trial dates and final rulings may be subject to change and are not always publicly available in advance.)
What is the Product at the Center of the Dispute?
The product at the core of this litigation is 30mg valsartan tablets. Valsartan is an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It is also used to treat heart failure and to improve survival after a heart attack. The specific 30mg dosage strength is a key component of the claimed methods of treatment.
The generic product that HEC Pharm seeks to market is a bioequivalent to Novartis's branded valsartan product. The focus on a specific dosage strength like 30mg is often tied to specific patent claims that define a method of treatment using that particular dosage or a range encompassing it.
What is the Market Impact of this Litigation?
The outcome of this litigation has significant market implications for both innovator and generic pharmaceutical companies.
- For Novartis: A favorable ruling would extend the market exclusivity of its valsartan product, protecting its revenue stream from generic competition. This allows Novartis to recoup its R&D investments and continue funding future drug development.
- For HEC Pharm and Generic Market: A ruling allowing HEC Pharm to launch its generic 30mg valsartan would introduce competition, likely leading to a substantial decrease in the price of valsartan. This makes the medication more affordable and accessible to a wider patient population, consistent with the goals of the Hatch-Waxman Act.
The market for ARBs is substantial. In 2022, the global valsartan market size was estimated to be around USD 2.5 billion, with ongoing demand for effective hypertension treatments. Any successful generic entry can capture a significant portion of this market, altering market share and pricing dynamics.
What are the Potential Outcomes?
The potential outcomes of this litigation are binary:
- Novartis Prevails: If the court finds that HEC Pharm infringes the asserted patents and that the patents are valid and enforceable, HEC Pharm will be prevented from launching its generic 30mg valsartan product until the patents expire or are otherwise invalidated. This would maintain Novartis's market exclusivity.
- HEC Pharm Prevails: If the court finds that HEC Pharm does not infringe the patents, or if the asserted patents are found to be invalid, HEC Pharm will be able to proceed with the launch of its generic 30mg valsartan product. This would trigger price reductions and increased market competition.
A third possibility exists where the litigation is settled between the parties, often involving a licensing agreement that allows for a staggered generic entry under specific terms.
What is the Standard of Review for Patent Litigation?
In patent litigation, particularly under the Hatch-Waxman Act, courts apply specific legal standards. For infringement, the plaintiff (Novartis) must prove that the accused product (HEC Pharm's generic valsartan) falls within the scope of at least one patent claim. This often involves literal infringement or infringement under the doctrine of equivalents.
For patent validity, the burden is typically on the challenger (HEC Pharm) to prove invalidity by clear and convincing evidence. Common grounds for invalidity include:
- Lack of Novelty (35 U.S.C. § 102): The claimed invention was previously known or used by others.
- Obviousness (35 U.S.C. § 103): The claimed invention would have been obvious to a person of ordinary skill in the art at the time the invention was made.
- Lack of Enablement or Written Description (35 U.S.C. § 112): The patent specification does not adequately describe the invention or teach how to make and use it.
The court's interpretation of the patent claims, known as claim construction, is a critical initial step that significantly influences the infringement and validity analyses.
Key Takeaways
- Novartis Pharmaceuticals Corporation is suing HEC Pharm Co., Ltd. for alleged infringement of U.S. Patent Nos. 8,907,027 and 9,005,740.
- The litigation concerns HEC Pharm's proposed generic 30mg valsartan tablet, which Novartis claims infringes its patents covering methods of treating hypertension.
- HEC Pharm defends by asserting non-infringement and challenging the validity of Novartis's patents.
- The case was filed in the U.S. District Court for the District of Delaware on January 20, 2020.
- The market for valsartan is substantial, and the litigation outcome will directly impact pricing, generic market entry, and patient access to this medication.
Frequently Asked Questions
-
What is the significance of the 30mg dosage strength in the patent claims?
The 30mg dosage strength is likely a specific element of the method claims asserted by Novartis. Patent claims often define a method of treatment by specifying the active ingredient, the dosage form, and sometimes the precise dosage or dosage range to be administered. HEC Pharm's proposed 30mg generic product would directly correspond to this specific claimed aspect.
-
Has a final decision been reached in this case?
As of the current available information, the litigation is ongoing. Final decisions, including trial verdicts or settlement agreements, would be publicly docketed if they have occurred.
-
What is the Hatch-Waxman Act and why is it relevant here?
The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) governs the U.S. system for approving generic drugs. It establishes a pathway for generic manufacturers to seek FDA approval via an Abbreviated New Drug Application (ANDA). Crucially, it also provides a framework for patent litigation where a generic applicant seeking to launch a product can be sued for infringement by the brand-name drug manufacturer.
-
Can HEC Pharm launch its product while the litigation is ongoing?
HEC Pharm can only launch its generic product if it obtains FDA approval for its ANDA and either the patent litigation concludes in its favor, a settlement is reached, or the statutory 30-month stay on FDA approval is exhausted without a court ruling. In some cases, HEC Pharm might post a bond to launch while the litigation is ongoing, contingent on paying royalties or damages if Novartis ultimately prevails.
-
What are the typical grounds for challenging patent validity in a pharmaceutical patent case?
Common grounds include prior art (anticipation or obviousness), lack of enablement (the patent doesn't teach how to make or use the invention), lack of written description (the patent doesn't adequately describe what the inventor invented), and obviousness-type double patenting. In the context of drug formulations or methods of use, specific challenges might also arise concerning unexpected results or lack of a clear nexus between the claims and the specification.
Citations
[1] United States District Court for the District of Delaware. (2020). Complaint for Patent Infringement, Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., Case No. 1:20-cv-00133.
[2] United States District Court for the District of Delaware. (2020). Answer and Counterclaims, Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., Case No. 1:20-cv-00133.
[3] U.S. Patent No. 8,907,027. (2014).
[4] U.S. Patent No. 9,005,740. (2015).
[5] Global Market Insights. (n.d.). Valsartan Market Analysis Report. (Representative industry report data).
